Allogene Therapeutics (ALLO) Earnings Analysis

Allogene Therapeutics (ALLO) next reports earnings on 2026-08-12, consensus EPS -0.16 USD. Last quarter (2026-03-12) it beat with EPS -0.17 USD vs -0.25 USD est (+32%). It has beaten estimates in 4/4 recent quarters (100%). Trailing P/E -2.42.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ALLO next report earnings?

Next earnings date2026-08-12
Consensus EPS estimate-0.16 USD
Revenue estimate0.00B

ALLO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-12-0.17 USD-0.25 USD+32%Beat
2025-11-06-0.19 USD-0.23 USD+17.4%Beat
2025-08-13-0.23 USD-0.28 USD+17.9%Beat
2025-03-13-0.28 USD-0.34 USD+17.6%Beat

Beat rate: 4/4 (100%) over reported quarters with consensus data.

ALLO valuation and analyst view

Trailing P/E-2.42
Trailing EPS-0.72312 USD
Price / book1.60
Dividend yield0.00%
Market cap0.45B
Analyst consensusBuy (19 buy / 10 hold / 1 sell)
Avg price target6.43 USD

Related research pages

Frequently asked questions

When is Allogene Therapeutics (ALLO)'s next earnings date?

Allogene Therapeutics is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -0.16 USD and revenue estimate of 0.00B.

Did ALLO beat earnings last quarter?

In its 2026-03-12 report, ALLO posted EPS of -0.17 USD versus a -0.25 USD estimate — a beat of 32%.

What is ALLO's earnings track record?

Over the last 4 reported quarters with consensus data, ALLO beat estimates 4 times (100%).

What is ALLO's current P/E ratio and EPS?

ALLO trades at a trailing P/E of -2.42 on trailing EPS of -0.7231238691461748 USD.

What do analysts rate ALLO?

Analyst consensus is "Buy" across 30 ratings (0 strong buy, 19 buy, 10 hold, 1 sell, 0 strong sell). Average 12-month price target: 6.43 USD.